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Abstract
Drug metabolism is a pharmacokinetic process whose main objective is to modify the 
chemical structure of drugs to easily excretable compounds. This process is carried out 
through phase I and phase II reactions. The enzymes of cytochrome P450 (CYP450) par-
ticipate in phase I reactions, and their activity can be inhibited or induced by xenobiotics. 
The aim of this chapter is to study the clinical relevance of the induction and inhibition 
of CYP450, by describing the effect that some bioactive compounds present in medici-
nal plants or foods can modify, either increasing or decreasing the activity of CYP450 
enzymes and with it modify the bioavailability and depuration of drugs. Examples will 
be described on the interaction of medicinal plants and foods of vegetal origin that when 
combined with some drugs can generate toxicity or therapeutic failure; this will allow 
gathering relevant information on the adequate pharmacological management in differ-
ent clinical situations.
Keywords: cytochrome P450, drug metabolism, medicinal plants, foods of vegetal 
origin toxicity, therapeutic failure
1. Introduction
When a patient is in pharmacological treatment, and at some point a pharmacological response 
different from the expected one is observed, it is possible to think that a pharmacological 
interaction occurred. This occurs when a drug is administered or consumed in combination 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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with other drugs, foods, or medicinal plants. In this context, changes in responses to drugs 
can be positive or negative for the patient. However, it is of particular interest to study the 
negative changes in pharmacological responses such as intoxication or therapeutic failure.
In this chapter, we focus on describing the effect of the interaction between drugs, medicinal 
plants, and foods of vegetable origin on the activity of cytochrome P450. Due to the natural 
products may modify the plasmatic concentrations of the drugs, either by inhibition or induc-
tion enzymatic, respectively.
In clinical practice, it is very important to know this topic to identify which medicinal plants 
and foods of vegetable origin should not be consumed when the patient is in pharmacological 
treatment and to avoid suffering a change in the response to medications that they consume 
by prescription and that could put their lives at risk.
2. General aspect of pharmacokinetics
To understand the effect of the chemical compounds, present in some medicinal plants and 
foods of vegetable origin on the activity of cytochrome P450 (CYP450), we will start with a 
brief description of the pharmacokinetics because the CYP450 participates in the phase I reac-
tions of drug metabolism.
Pharmacokinetics is the branch of pharmacology that is responsible for studying and explain-
ing the processes by which drugs are absorbed, distributed, metabolized, and eliminated 
from organism [1, 2]. It is important to know these pharmacokinetics processes and how they 
influence the bioavailability of drugs [2].
Bioavailability refers to the amount of drug found in the bloodstream and is available to exert 
its pharmacological effect [3]. However, if the plasma quantity of a drug is modified, the phar-
macological response will be modified [1–3]. The four pharmacokinetic processes influence 
the bioavailability of the drugs. In the process of metabolism, the plasma concentrations of 
the drugs can be modified, either by inhibition or by induction of different CYP isoenzymes, 
as shown in Figure 1.
The following example makes it easier to understand the importance of adherence to treat-
ment to avoid fluctuations in plasmatic concentration. When patients are in pharmacological 
treatment, it is important that dosage regimen be complied. For example, if the prescription 
is 500 mg of acetaminophen every 8 h, this patient should be taken exactly three tablets of 
500 mg of acetaminophen per day.
In order for patient has an adequate pharmacological response to acetaminophen, and a lower 
probability of presenting adverse effects or therapeutic failure, the amount of drug and the 
time of administration indicated in each shot must be respected. If, patient modifies any of 
these two variables, the plasma concentration of the drug changes and with it its response 
also changes [4].
When a single dose of drug is administered orally, after a certain time, the plasma concen-
trations of the drug are enlarged until reaching a maximum level. This maximum point is 
known as maximum plasma concentration (C
max
), and it is reached in a determined maximum 
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time (t
max
). These parameters are specific for each drug [6]. The C
max
 of a drug is within the 
therapeutic range [4].
On the other hand, after several administrations of a drug, the final concentration begins to 
increase due to the remainder of the previous dose, until reaching a constant concentration called 
the equilibrium state [1]. Steady state is usually achieved after four to five half-lives [1, 2]. The half-
life (t
1/2
) is defined as the time required by a drug to decrease its initial concentration by half [1].
In the equilibrium state, the drug plasmatic concentrations are within the range of therapeutic 
effect. If the patient suspends the administration of the drug, the plasma levels fall to concen-
trations below the therapeutic level causing therapeutic failure. Generally, the elimination of 
a drug is carried out after four to five half-lives [1–3].
When the patient does not remember if took the dose of the drug and decides to take the dose 
thinks was needed, the concentration of that drug will accumulate, then the plasma concentration 
reaches levels above the therapeutic concentration, and additionally, some signs of toxicity begin 
to appear [5].
In this chapter, we will focus on describing the effect that some compounds present in 
medicinal plants and some foods of vegetable origin can have on the activity of cytochrome 
P450 enzymes. The World Health Organization (WHO) estimates that more than 80% of 
Figure 1. Effect of drug metabolism on the pharmacological response.
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the population of developed and underdeveloped countries use medicinal plants as a first 
resource for their health care and, on the other hand, there is a context cultural acceptance 
of the traditional practice with herbs, which makes its use popular and that in many cases 
patients combine their pharmacological treatment with herbal treatment [6–10].
On the other hand, the consumption of certain foods of vegetable origin with nutraceutical 
properties has increased considerably in recent years, especially to treat and prevent condi-
tions such as cancer, diabetes, hypertension, hypercholesterolemia, obesity, among others. 
Therefore, by combining these foods with the pharmacological treatment indicated in the 
abovementioned conditions, they can significantly modify the plasma levels of some drugs 
and put the patient’s life at risk, either due to therapeutic failure (decrease in plasma concen-
tration) or toxicity (increased plasma concentration) [11–15].
2.1. Pharmacokinetic process of drug metabolism
The drugs are defined chemically as acids or weak bases, and during the absorption process, 
the nonionized fraction of a drug is the one that crosses the biological membranes, due to 
its lipid solubility. Until the condition of lipid solubility is not lost, the drug will continue 
remaining in the body, by means of processes of reabsorption at the renal level or the entero-
hepatic circuit and redistribution from drug deposits in adipose tissue [16–19].
If this lipid solubility condition is not lost, the drug will not be able to be eliminated [2, 18]. 
Fortunately, the pharmacokinetic process of the metabolism helps to modify the chemical struc-
ture of drugs into structures more polar, so that these can be more easily excreted [2, 18, 19].
The main organ that participates in the metabolism of drugs and other xenobiotics is the liver. 
However, other tissues also have metabolic capacity such as the gastrointestinal tract, lungs, 
skin, kidneys, and brain [20–23].
The functional unit of this organ is the hepatocyte, and it contains different enzymes that are 
in the mitochondria, smooth and rough reticulum membrane, cytosol, etc. [23].
During this process of drug metabolism, the following may occur:
1. Transform to a more active molecule [1–3].
2. Transform to give biological activity (prodrug) [1–3].
3. Transform to an inactive molecule [1–3].
4. Transform to a toxic molecule [1–3].
It is important to mention that there are drugs that do not transform. Their chemical structure 
is not modified, and they are eliminated unaltered [2].
2.1.1. Effect of metabolism of the first step
When drugs are administered orally, they suffer a phenomenon of elimination prior to the 
process per se of the metabolism. This effect is known as first-pass metabolism and occurs in 
the epithelial cells of the gastrointestinal tract mainly in the small intestine [24]. Subsequently, 
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the amount of drug that was not biotransformed enters the liver through the portal circulation, 
and there in the hepatocytes the metabolism process per se is carried out [24]. The amount 
of drug remaining after liver extraction is bioavailable to give an adequate pharmacological 
response. It is important not to modify this bioavailability because the effective doses of the 
drugs used in the clinical ready are considered as the effect of metabolism of the first step. 
Above all, caution should be exercised in drugs with a narrow safety margin, such as barbi-
turates [1, 2].
2.1.2. Enterohepatic circuit
When drugs are biotransformed by phase I reactions, and the molecule obtained is not polar 
enough to be eliminated, their biotransformation continues through phase II reactions. In 
this phase, the metabolites are generally conjugated with glucuronide acid, giving a polar 
molecule with a higher molecular weight [1, 2]. These conjugates are secreted from the hepa-
tocyte into the bile and stored there in the form of a drug-glucuronide complex; when the bile 
is secreted in the intestine by some stimulus, the drug-bile complex is eliminated through 
the feces [25]. However, intestinal microorganisms produce various enzymes, such as beta-
glucuronidases, which break the bond between the drug and glucuronide acid, leaving the 
drug free again, where it can be reabsorbed through the small intestine and enter the general 
circulation. In this case, the half-life of the drugs is increased [25].
2.1.3. Factors that affect the metabolism of drugs
2.1.3.1. Physiological factors: age and pregnancy
In children and older adults, the metabolic rate is decreased compared to the metabolic rate 
of a young adult [1]. In the child, the microsomal enzymes are not yet fully induced [26]. In 
elderly people, the number of hepatocytes and blood flow that reaches this organ is reduced 
[27]. So, there are fewer cytochrome P450 enzymes available to metabolize drugs. In preg-
nancy, there is greater hepatic flow and greater activity of cytochrome P450, which increases 
the metabolic rate [28].
2.1.3.2. Pathological factors: liver disease
The number of hepatocytes decreases, and the metabolic rate also decreases. In addition, there 
is an increase in the plasmatic concentrations and half-life of drugs. Therefore, it is necessary 
to adjust the dose, to prevent toxicity [2].
2.1.3.3. Drugs, medicinal plants, and foods
Some drugs and phytochemical compounds present in medicinal plants and foods of plant 
origin can induce or inhibit the activity of cytochrome P450 [29].
2.2. Phases of drug metabolism
Biotransformation reactions of drugs are divided into reactions of phase I or functionalization 
and reactions of phase II or conjugation [2].
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The chemical reactions of phase I allow the introduction of functional groups such as –OH, 
–COOH, –SH, –O–, or –NH
2
. Phase I reactions are very simple chemical reactions such as 
oxidation, reduction, hydrolysis, alkylation, and dealkylation [2]. Of these chemical reactions, 
the most important in the metabolism of drugs and that occur more frequently are the oxi-
dation reactions performed by the cytochrome P450 enzymes (CYP450). These enzymes are 
located mainly in the smooth endoplasmic reticulum [1, 2].
When the addition of the functional groups (–OH, –COOH, –SH, –O–, –NH
2
) to the drug 
molecule is not enough to transform it to a more polar molecule, the molecule continues 
its modification through reactions of phase II. Phase II reactions are called also conju-
gation reactions. In these reactions, the molecule of the drug or metabolite previously 
formed in the reactions of phase I is conjugated with a large molecule of polar nature 
(hydrophilic) as the acid glucuronide, or acetyl Co-A, glycine, glutathione, phosphoad-
enosyl phosphosulfate, and S-adenosylmethionine [2]. These reactions are carried out by 
means of specific enzymes called transferases that are generally located in the microsomes 
and in the cytosol [1–3].
2.3. Role of cytochrome P450 (CYP450) in drug metabolism
Cytochrome P450 (CYP450) is a superfamily of enzymes that contain a heme group, so they 
are hemoproteins. The iron in the heme group is reduced and forms complexes with the car-
bon monoxide that absorbs light at a wavelength of 450 nm [30]. They have identified more 
than 8700 genes that code for their proteins and are found in eukaryotic and prokaryotic cells 
[31]. They are responsible for metabolizing or biotransforming endogenous substances in the 
body such as hormones, and different xenobiotics such as drugs. These enzymes perform 
oxidation reactions and participate in the phase I reactions of drug metabolism [1–3]. They 
are also known as mixed function oxidases or monooxygenases; they require a reducing agent 
such as NADPH and molecular oxygen [32].
They have different patterns of specificity for the substrate; for example, acetaminophen is 
a substrate of both CYP1A2 and CYP2E1, while halogenated anesthetics are substrate only 
of CYP2E1 [2, 34–36]. This enzyme system is found in different tissues such as kidney, lung, 
skin, brain, adrenal cortex, placenta, testicles, and other tissues, but the liver and small intes-
tine are the organs that have more CYP450 [33, 34].
2.3.1. Nomenclature of CYP450
The CYP450 is grouped into families and subfamilies depending on the analogy in their 
amino acid sequences, such that CYPs that present 40% homology in their amino acids belong 
to a family, and when the analogy is greater than 55%, they form a subfamily, are named with 
the prefix CYP, and followed by the family number, a capital letter indicating the subfamily, 
and a number that marks the individual form: for example, CYP1A1, in this way, represents 
the individual form 1 of subfamily A of family 1 [35]. Eighteen families, 42 subfamilies, and 
more than 50 individual genes of human origin have been described. However, the most 
important in the metabolism of drugs are CYP1A1/2, CYP1B1, CYP2A6, CYP2B6, CYP2C9, 
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CYP2D6, CYP2E1, CYP3A4,5,7 [1–3]. CYP3A4,5,7 is the most abundant and participates in the 
metabolism of more than 50% of the drugs currently used in the clinic [1–3, 35].
2.4. Induction and Enzymatic inhibition
Many substances such as drugs, environmental toxins, and phytochemicals present in 
medicinal plants and some foods of plant origin contain substances that act as inhibitors or induc-
ers of cytochrome P450 enzymes; this induction and inhibition can be strong or weak so it can 
sometimes have relevant clinical implications such as producing toxicity or therapeutic failure [36].
Enzymatic induction refers to the increase of enzymes and/or their activity. Additionally, it 
increases the metabolic rate of CYP450, and therefore, the concentrations of the drug in blood 
will decrease, which can cause a decrease in pharmacological effects and with it a therapeutic 
failure (Figure 2) [37].
In enzymatic inhibition, the number of enzymes and/or their activity decreases. There are 
fewer enzymes available to biotransform the drugs and increase their plasma levels with each 
administration of the drug will produce toxicity (Figure 2) [33].
It is important not to induce or inhibit the activity of CYP450; they directly influence the 
bioavailability of the drugs. On the other hand, the genetic polymorphism of CYP450 is also 
responsible for the variability in the response to drugs between each individual [34, 35]. 
Genetic variability, especially of CYP2C9, CYP2C19, CYP2D6, and CYP3A5, is known to 
have an important clinical impact on drugs that are metabolized by these enzymes [38–40].
2.5. Effect of bioactive compounds of medicinal plants and foods of vegetable origin 
on the activity of CYP450
In the literature, there is a lot of information about the effect of drugs to inhibit or induce cer-
tain CYP450 isoenzymes. Recently  the study of the effect of some phytochemical components 
that are present in medicinal plants and foods of vegetable origin on the activity of CYP450 
has been increasing, because the population makes use of herbal medicine in its traditional 
practice and, on the other hand, it consumes foods with nutraceutical properties, either to 
prevent or to control any disease.
Figure 2. Effect of medicinal plants and foods of vegetable origin on CYP450 activity.
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Medicinal 
plant
Tradicional uses Phytochemistry 
compounds
Activity on 
CYP450
Clinical effect 
on substrates of 
CYP450
References
Artemisia  
annua L.
Antimalaria effect Artemisinin ↑CYP2C19 ↓Plasmatic 
concentration of I
[3, 41, 42]
Cimicifuga 
racemosa
Are used as 
a hormone 
replacement and 
antiinflammatory
Triterpene 
glycosides Fukinolic 
acid 
Cimicifugic acid A
Cimicifugic acid B
↓CYP1A2 
↓CYP2D6 
↓CYP2C9
↓CYP3A4
↑Plasmatic 
concentration of II
↑Plasmatic 
concentration of III
↑Plasmatic 
concentration 
of IV
↑Plasmatic 
concentration of V
[3, 43]
Centella asiatica Used for wound 
healing and 
maintaining normal 
blood pressure.
Flavonoids: 
Quercetin 
Kaempferol
↓CYP2D6 
↓CYP2C9 
↓CYP3A4
↑Plasmatic 
concentration of III
↑Plasmatic 
concentration 
of IV
↑Plasmatic 
concentration of V
[3, 44, 45]
Curcuma longa Antiinflammatory, 
anticancer and 
antiarthritic effect.
Curcuminoids:  
Curcumin 
Methoxycurcumin, 
Bisdemethoxy- 
curcumin
↓CYP1A2 
↑CYP2A6 
↓CYP2C9 
↓CYP3A4
↑Plasmatic 
concentration of II
↓Plasmatic 
concentration 
of VI
↑Plasmatic 
concentration 
of IV
↑Plasmatic 
concentration of V
[3, 46–48]
Echinacea 
purpurea (L.)
It is used to treat 
colds, upper 
respiratory 
infections, and 
dermatologic issues
Cichoric acid  
Caftaric acid  
Echinacoside 
Alkylamides
↑CYP1A2 
↓CYP3A4
↓Plasmatic 
concentration of II
↑Plasmatic 
concentration of V
[3, 49, 50]
Garcinia 
cambogia
Obesity treatment Extract crude ↓CYP2B6 ↑Plasmatic 
concentration 
of VII
[3, 51]
Gardenia 
jasminoides 
Ellis.
Is used as an 
antioxidant, 
hypoglycemic , 
antithrombotic, 
antiinflammatory, 
antidepression 
effect, and improved 
sleeping quality
Geniposide  
Genipin
↑CYP2D6 
↓CYP2C19 
↓CYP3A4
↓Plasmatic 
concentration of III
↑Plasmatic 
concentration of I
↑Plasmatic 
concentration of V
[3, 52, 53]
Gingko biloba It is used as an anti-
hypertensive as well 
as to treat macular 
degeneration 
and tinnitus. Are 
effective in treating 
cerebral infarction
Ginkgolide A
Ginkgolide B 
Bilobalide  
Quercetin  
kaempferol
↓CYP2B6 
↑CYP1A2
↑CYP3A4
↑Plasmatic 
concentration 
of VII
↓Plasmatic 
concentration of II
↓Plasmatic 
concentration of V
[3, 54–56]
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Medicinal 
plant
Tradicional uses Phytochemistry 
compounds
Activity on 
CYP450
Clinical effect 
on substrates of 
CYP450
References
Panax ginseng Is believed to 
enhance cognitive 
ability and to lower 
blood sugar levels 
Ginsenosides and 
gintonin
Ginsenoside F2 and 
protopanaxadiol
Ginsenosides ↓CYP2C9
↓CYP3A4
↑Plasmatic 
concentration 
of IV
↑Plasmatic 
concentration of V
[3, 57]
Camellia 
sinensis
It is consumed 
to treat cancer, 
cardiovascular 
disease, 
dyslipidemia, 
inflammation, and 
weight loss
Catechin
(-)-Epigallocatechin -3- 
gallate
↓CYP1A2
↓CYP2B6
↓CYP2C8
↓CYP2C9
↓CYP2D6
↓CYP3A4
↑Plasmatic 
concentration of II
↑Plasmatic 
concentration 
of VII
↑Plasmatic 
concentration 
of VIII
↑Plasmatic 
concentration of IV
↑Plasmatic 
concentration of III
↑Plasmatic 
concentration of V
[3, 58–60]
Piper 
methysticum
Anxiolytic effect Flavokawain A ↑CYP2C9
↓CYP1A2
↓CYP3A4
↓Plasmatic 
concentration 
of IV
↑Plasmatic 
concentration of II
↑Plasmatic 
concentration of V
[3, 61–64]
Hypericum 
perforatum
Is used to treat 
anxiety and 
depression
Hyperforin ↑CYP2C9
↑CYP3A4
↓Plasmatic 
concentration 
of IV
↓Plasmatic 
concentration of V
[3, 65–67]
I: Omeprazole, pantoprazole, diazepam, S-mephenytoin, amitriptyline, carisoprodol, citalopram, chloramphenicol, 
clomipramine, cyclophosphamide, indomethacin, moclobemide, nelfinavir, propranolol, progesterone.
II: Acetaminophen, amitriptyline, phenacetin, tacrine, theophylline, tamoxifen, (R)warfarin, caffeine, verapamil, 
ondansetron, haloperidol, naproxen, propanolol.
III: Propoxyphene, codeine, oxycodone, dextromethorphan, clozapine, timolol, tamoxifen, tramadol, seleglinide, 
fluoxetine, phenformin, paroxetine, risperidone, metoprolol, tricyclic antidepressants.
IV: Amitriptyline, celcoxib, ibuprofen, diclofenac, meloxicam, hexobarbital, losartan, S-warfarin, fluvastation, phenytoin, 
tolbutamide, glipizide, glibenclamide, fluoxetine, tamoxifen.
V: Acetaminophen, amiodarone, cisapride, astemizole, cocaine, cyclosporine, dapsone, diazepam, dihydroergotamine, 
diltiacem, felodipine, nifedipine, erythromycin, indinavir, lidocaine, methadone, miconazole, quinidine, paclitaxel, 
mifepristone, spironolactone, verapamil, trazolam, desametaxone, ritonavir, lovastatin, hydrocortisone.
VI: Nicotine.
VII: Bupropion, cyclophosphamide, efavirenz, ifosfamide, methadone.
VIII: Paclitaxel, torsemide, amodiaquine, cerivastatin, repaglinide.
Table 1. Effect of medicinal plants on CYP450 activity.
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Tables 1 and 2 show the effect of the phytochemical compounds present in medicinal plants 
and foods of vegetable origin. We mentioned principally those natural products that have 
an important effect on the induction and inhibition of different CYP450 isoenzymes and that 
have clinical relevance to produce toxicity or therapeutic failure.
3. Conclusions
The induction and inhibition of CYP450, by some bioactive compounds present in medicinal 
plants or foods, can modify the bioavailability of drugs. The changes in the bioavailability 
are important in the efficacy and safety of pharmacological management. It is important to 
consider that when a patient will be in a pharmacologic treatment, the patient should not 
use any medicinal plants or foods of vegetable origin that can induce or inhibit any CYP450 
isoenzymes.
Especially, they should not use the St. John’s wort and grapefruit, as their phytochemical 
compounds have a potent effect to induce or inhibit, respectively, the activity of CYP3A4 with 
important clinical relevance.
Fruit or vegetable Phytochemistry 
compound
Activity on 
CYP450
Clinical effect on substrates 
of CYP450
References
Broccoli Sulforaphane ↑CYP1A2 
↓CYP2D6
↓Plasmatic concentration of II
↑Plasmatic concentration of III
[3, 68, 69]
Grapefruit Furanocoumarin ↓CYP3A4 ↑Plasmatic concentration of V [3, 65, 70, 71]
Pomegranate Flavonoids 
Tannins 
Phenolic acids
↓CYP2C9 
↓CYP3A4
↑Plasmatic concentration of IV
↑Plasmatic concentration of V
[3, 72]
Sevillian orange Furanocoumarin ↓CYP3A4 ↑Plasmatic concentration of V [3, 73]
Star fruit Catechin Epicatechin ↓CYP3A4 ↑Plasmatic concentration of V [3, 74–76]
II: Acetaminophen, amitriptyline, phenacetin, tacrine, theophylline, tamoxifen, (R)warfarin, caffeine, verapamil, 
ondansetron, haloperidol, naproxen, propanolol.
III: Propoxyphene, codeine, oxycodone, dextromethorphan, clozapine, timolol, tamoxifen, tramadol, seleglinide, 
fluoxetine, phenformin, paroxetine, risperidone, metoprolol, tricyclic antidepressants.
IV: Amitriptyline, celcoxib, ibuprofen, diclofenac, meloxicam, hexobarbital, losartan, S-warfarin, fluvastation, phenytoin, 
tolbutamide, glipizide, glibenclamide, fluoxetine, tamoxifen.
V: Acetaminophen, amiodarone, cisapride, astemizole, cocaine, cyclosporine, dapsone, diazepam, dihydroergotamine, 
diltiacem, felodipine, nifedipine, erythromycin, indinavir, lidocaine, methadone, miconazole, quinidine, paclitaxel, 
mifepristone, spironolactone, verapamil, trazolam, desametaxone, ritonavir, lovastatin, hydrocortisone.
Table 2. Effect of fruits or vegetables on CYP450 activity.
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